Azurocidin Monoclonal Antibody (z6718), Invitrogen™

Description

• In Western Blot application testing, this antibody detected a 37 kDa protein
• A non-reduced sample treatment and SDS-Page was used
• Product is supplied at 1 mL (100 μL/mL)
• Azurocidin, also called heparin-binding protein (HBP), is an inactive homolog of serine proteinases residing in granulocytes
• Initially it was thought to have only activity against gram-negative bacteria
• Later it was also found to act against gram-positive bacteria and C
• albicans
• Azurocidin is considered a family member of polymorphonuclear leukocytes- derived antimicrobial proteins like defensins, LL-37 and lysozyme
• Azurocidin has been recognized as a player in the activation and modulation of the immune response and may act to alarm the immune system
• The cationic domain at one side of the protein is essential for its antimicrobial activity
• It is stored in azurophil granules as well as secretory granules and as a result partly released at early stage of extravasation
• Azurocidin is involved in chemotaxis and activation of monocytes, cytokine release and phagocytosis leading to more efficient bacterial clearance
• The primary targeted environment of azurocidin are cells in the bloodstream, that is the endothelial lining, and the extravascular surroundings
• The interaction of azurocidin with leucocytes is mediated via beta 2-intergrins
• High plasma levels of azurocidin might help with the identification of patients which are at risk in developing sepsis.